Adam Walsh
Stock Analyst at Roth Capital
(2.76)
# 2,351
Out of 5,182 analysts
16
Total ratings
64.29%
Success rate
20%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Initiates: Buy | $12 | $2.03 | +491.92% | 1 | Mar 13, 2026 | |
| APLS Apellis Pharmaceuticals | Initiates: Buy | $31 | $40.87 | -24.14% | 1 | Mar 13, 2026 | |
| INSM Insmed | Initiates: Buy | $212 | $148.96 | +42.32% | 1 | Jan 23, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $38.26 | +51.61% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $246.20 | -30.54% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $29.09 | +546.27% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $44.02 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $25.04 | +207.51% | 1 | Apr 18, 2018 |
Equillium
Mar 13, 2026
Initiates: Buy
Price Target: $12
Current: $2.03
Upside: +491.92%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $40.87
Upside: -24.14%
Insmed
Jan 23, 2026
Initiates: Buy
Price Target: $212
Current: $148.96
Upside: +42.32%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $38.26
Upside: +51.61%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $246.20
Upside: -30.54%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $29.09
Upside: +546.27%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $44.02
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $25.04
Upside: +207.51%